Arrowstreet Capital Limited Partnership Purchases New Position in Haleon plc (NYSE:HLN)

Arrowstreet Capital Limited Partnership acquired a new position in shares of Haleon plc (NYSE:HLN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 935,260 shares of the company's stock, valued at approximately $8,922,000.

Several other institutional investors have also recently modified their holdings of HLN. Addison Advisors LLC lifted its holdings in Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,106 shares in the last quarter. Synovus Financial Corp raised its position in shares of Haleon by 0.8% in the third quarter. Synovus Financial Corp now owns 148,834 shares of the company's stock valued at $1,575,000 after buying an additional 1,216 shares during the last quarter. Haverford Trust Co lifted its stake in shares of Haleon by 5.0% during the fourth quarter. Haverford Trust Co now owns 25,842 shares of the company's stock valued at $247,000 after buying an additional 1,233 shares during the period. Greenleaf Trust lifted its stake in shares of Haleon by 8.4% during the fourth quarter. Greenleaf Trust now owns 17,225 shares of the company's stock valued at $164,000 after buying an additional 1,333 shares during the period. Finally, Baron Wealth Management LLC boosted its position in Haleon by 4.3% during the fourth quarter. Baron Wealth Management LLC now owns 33,632 shares of the company's stock worth $321,000 after acquiring an additional 1,381 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Trading Up 4.3 %

Shares of HLN traded up $0.42 during trading hours on Friday, hitting $10.05. The stock had a trading volume of 16,215,293 shares, compared to its average volume of 6,973,856. Haleon plc has a 12-month low of $7.99 and a 12-month high of $10.80. The firm has a market cap of $45.38 billion, a P/E ratio of 29.54, a P/E/G ratio of 2.82 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The company's fifty day simple moving average is $10.04 and its 200 day simple moving average is $9.82.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The company had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Equities research analysts forecast that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. This is a positive change from Haleon's previous -- dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. Haleon's dividend payout ratio (DPR) is presently 58.97%.

Wall Street Analysts Forecast Growth

HLN has been the subject of several analyst reports. HSBC reiterated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Sanford C. Bernstein lowered Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Morgan Stanley downgraded Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Haleon presently has an average rating of "Hold" and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.